Results 21 to 30 of about 675,523 (296)

Heterologous prime–boost strategies for COVID-19 vaccines [PDF]

Journal of Travel Medicine, 2021
Abstract Background/Objective Heterologous prime–boost doses of COVID-19 vaccines (‘mix-and-match’ approach) are being studied to test for the effectiveness of Oxford (AZD1222), Pfizer (BNT162b2), Moderna (mRNA-1273) and Novavax (NVX-CoV2373) vaccines for COVID in ‘Com-Cov2 trial’ in UK, and ...
Binaya Sapkota, Bhuvan Saud, Ranish Shrestha, Dhurgham Al-Fahad, Ranjit Sah, Sunil Shrestha, Alfonso J Rodriguez-Morales   +6 more
openaire   +2 more sources

Alternating 3 different influenza vaccines for swine in Europe for a broader antibody response and protection

Veterinary Research, 2022
Heterologous prime-boost vaccination with experimental or commercial influenza vaccines has been successful in various animal species. In this study, we have examined the efficacy of alternating 3 different European commercial swine influenza A virus ...
Anna Parys, Elien Vandoorn, Koen Chiers, Kristien Van Reeth   +3 more
doaj   +1 more source

Heterologous prime boost COVID 19 vaccination

Infectious Diseases Now, 2022
Heterologous prime boost vaccination is a primary vaccination with different vaccines, most often from different vaccine platforms. It combines the immunological properties of the different vaccines and thereby induces humoral, cellular and, in some cases, mucosal response.
Launay, O., Thill, P.
openaire   +2 more sources

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

The Lancet Regional Health. Europe, 2021
Summary: Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we ...
Peter Nordström, Marcel Ballin, Anna Nordström   +2 more
doaj   +1 more source

DataSheet_1_In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant.pdf

, 2022
With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants of Concern (VOCs), vaccination studies that elucidate the efficiency and effectiveness of a vaccination campaign are critical to assess the durability and ...
Matthias Tenbusch (85322), Stephanie Pfänder (14287934), Ingo Schmitz (520756), Toralf Roch (4240687), Clara Bessen (9117066), Ulrik Stervbo (2557699), Sandra Busse (10938663), Wolfgang Ekkehard Schmidt (14287928), Doris Urlaub (5611730), Markus Hoffmann (223014), Stefan Pöhlmann (142445), Daniel Robert Quast (14287931), Natalie Heinen (10642370), Eike Steinmann (32663), Daniel Todt (777446), Jil Schrader (3364673), Elena Vidal Blanco (14206799), Carsten Hagenbeck (5143943), Moritz Anft (11995520), Nina Babel (844503), Corinna Sophie Marheinecke (14287922), Gert Zimmer (223023), Mara Klöhn (14287925), Arturo Blazquez-Navarro (5203973), Carsten Watzl (208203), Carlos Plaza-Sirvent (11334660)   +25 more
core   +1 more source

Prime–boost approaches to tuberculosis vaccine development [PDF]

Expert Review of Vaccines, 2012
Four individuals die from active TB disease each minute, while at least 2 billion are latently infected and at risk for disease reactivation. BCG, the only licensed TB vaccine, is effective in preventing childhood forms of TB; however its poor efficacy in adults, emerging drug-resistant TB strains and tedious chemotherapy regimes, warrant the ...
Neha, Dalmia, Alistair J, Ramsay
openaire   +2 more sources

Prime-boost vaccination of hACE2 transgenic mice induces high levels of neutralizing antibodies against SARS-CoV-2.

, 2021
Six-week-old female hACE2 transgenic mice were prime vaccinated with rVSVInd-msp-SF-Gtc and boost immunized with rVSVInd-msp-SF-Gtc or rVSVNJ-msp-SF-Gtc two weeks after the prime-vaccination.
Taewoo Kim (1456888), Ryan M. Troyer (11846435), Sun-Je Woo (10336425), Eric J. Arts (11846438), Kunyu Wu (11846408), S. M. Mansour Haeryfar (8069414), Jung-ah Choi (6520727), Seungho Choo (11846423), Gregory A. Dekaban (9694262), Brock Fenton (359975), Gyoung Nyoun Kim (11846405), Gippeum Lim (7253675), Na Hyung Kim (1315179), Nasrin Saeedian (11846411), Kate Parham (11846429), Jae-Hyung Chang (327325), Andrew Winterborn (11846426), Hoe Won Jeong (11846420), Eunsil Choi (8271039), Justin M. Donovan (11846432), Su-Kyeong Eo (11846417), Jimmy D. Dikeakos (8871386), Manki Song (317984), Yue Li (102191), Hayan Park (9182877), Eunji Yang (9182871), Seong-Gyu Kim (11846414), C. Yong Kang (11846444), Sangkyun Lee (312151), Sang Hwan Seo (10838327), Stephen D. Barr (11846441)   +30 more
core   +1 more source

Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. [PDF]

PLoS ONE, 2013
This study analyzed a heterologous prime-boost vaccine approach against HIV-1 using three different antigenically unrelated negative-stranded viruses (NSV) expressing HIV-1 Gag as vaccine vectors: rabies virus (RABV), vesicular stomatitis virus (VSV) and
Tessa M Lawrence, Celestine N Wanjalla, Emily A Gomme, Christoph Wirblich, Anthony Gatt, Elena Carnero, Adolfo García-Sastre, Douglas S Lyles, James P McGettigan, Matthias J Schnell   +9 more
doaj   +1 more source

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles [PDF]

, 2011
Background: There is renewed interest in the development of poxvirus vector-based HIV vaccines due to the protective effect observed with repeated recombinant canarypox priming with gp120 boosting in the recent Thai placebo-controlled trial.
Bridge, S., Skinner, Michael A., Anson, Donald, Dennis, M., Simon H Bridge, Dowall, S., Blanchard, Tom J., Getty, B., Stewart, James, Dennis, Mike J., Dowall, SD, Donald S Anson, Anson, D., Dennis, MJ, Bridge, Simon H., Dowall, Stuart D., Blanchard, Thomas, Stewart, JP, Blanchard, T., Skinner, M., Stewart, James P., James P Stewart, Mike J Dennis, Getty, B, Michael A Skinner, Bridge, SH, Bridge, Simon, Sharpe, Sally, Sharpe, SA, Skinner, MA, Getty, Brian, Brian Getty, Dennis, Mike, Blanchard, Tom, Sharpe, Sally A., Anson, DS, Sally A Sharpe, Skinner, Michael, Stuart D Dowall, Tom J Blanchard, Blanchard, TJ, Anson, Donald S., Stewart, J., Sharpe, S., Dowall, Stuart, Sharpe Sally A, Skinner Michael A, Dowall Stuart D, Dennis Mike J, Blanchard Tom J, Stewart James P, Anson Donald S, Bridge Simon H, Getty Brian   +53 more
core   +1 more source

Prime-boost strategies for malaria vaccine development [PDF]

Journal of Experimental Biology, 2003
SUMMARYMalaria is an intracellular pathogen, for which an effective vaccine is likely to require induction of cell-mediated immunity. Immunisation approaches that stimulate strong and persistent levels of effector T-cells are being sought by many researchers.
Dunachie, S, Hill, A
openaire   +3 more sources